Document 0966
 DOCN  M9460966
 TI    Is there any predictive factor of the clinical response to IL2 therapy
       in metastatic malignant melanoma (Meeting abstract).
 DT    9406
 AU    Soubrane C; Mouawad R; Ichen M; Suissa J; Vuillemin E; Borel C;
       Benhammouda A; Weil M; Khayat D; Oncology Medical Lab., Salpetriere
       Hosp., 75013 Paris, France
 SO    Fourth International Congress on Anti-cancer Chemotherapy. February 2-5,
       1993, Paris, France, p. 99, 1993.. Unique Identifier : AIDSLINE
       ICDB/94697771
 AB    Immunological parameters following chemo-immunotherapy combination were
       studied in 31 patients with metastatic malignant melanoma. They received
       cisplatin (100 mg/m2) at day 1 and 28, r-interleukin-2 (IL2, Eurocetus)
       in continuous infusion from day 3-6, 17-21, 31-34 and 45-49. Alpha
       interferon (Roche) was given sc three times weekly. No significant
       change in CD4/CD8 ratio both at onset or during treatment was observed
       between responder (n = 19) and nonresponder (n = 11) patients. Regarding
       IL2 receptor study, the percentage of cells expressing TAC (p55)
       receptor did not change either between healthy volunteers (n = 20) and
       patients before any therapy or between responder and nonresponder
       patients. Concerning soluble IL2R shedding before any therapy, we
       observed a significant increase (p = 0.001) in patients (79 +/- 40 PM)
       compared to healthy donors (30.6 +/- 15 PM) but no significant variation
       was seen between responder and nonresponder patients. In contrast,
       during the treatment, the soluble IL2R ratio increased in both groups
       but, interestingly a significant difference was found between responder
       and nonresponder patients from day 7 (p less than 0.05) to day 21 (p
       less than 0.01) suggesting that the cells from nonresponder may be
       slower in becoming stimulated. It is the most striking point of our
       study since sIL2R might be an early predictive factor of the clinical
       response as obtained by logistic regression (p = 0.0063).Therefore
       patients with a soluble IL2R level greater than 250 PM have 12-fold more
       chances to present a clinical response.
 DE    CD4-CD8 Ratio  Cisplatin/*ADMINISTRATION & DOSAGE  Human
       Interferon-alpha/THERAPEUTIC USE  Interleukin-2/*ADMINISTRATION & DOSAGE
       Melanoma/DRUG THERAPY/METABOLISM/PATHOLOGY/*THERAPY  Receptors,
       Interleukin-2/METABOLISM  MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).